Entera Bio Expands Collaboration with OPKO Health for New Oral LA-PTH Program; Appoints OPKO Executive to Board
ENTX is trading near its 52-week low of $1.23 (4.1% below the low) on elevated volume (2.0× avg).
Summary
Entera Bio Ltd. announced an expanded collaboration agreement with OPKO Health to include a new oral long-acting PTH (LA-PTH) program for hypoparathyroidism with 50/50 cost-sharing, alongside the appointment of OPKO's Executive VP, Steven D. Rubin, to its Board of Directors.
Key Events · M&A and Partnerships · ENTX
-
Collaboration Expanded for New LA-PTH Program
Entera Bio and OPKO Health amended their collaboration to include a new oral long-acting PTH (LA-PTH) program for hypoparathyroidism, with development costs to be shared equally (50/50).
-
Accelerated Development Timeline
Following favorable preclinical data in December 2025, the LA-PTH program's development has been accelerated, targeting an Investigational New Drug (IND) application filing with the FDA in late 2026.
-
OPKO Executive Appointed to Board
Steven D. Rubin, Executive Vice President of Administration and a director at OPKO Health, was appointed as a Class III director to Entera's Board, also becoming Chairman of the audit committee, strengthening strategic ties and governance.
Analysis · ENTX · Life Sciences
Entera Bio has significantly expanded its collaboration with OPKO Health, adding a new oral long-acting PTH (LA-PTH) program for hypoparathyroidism. This expansion is a material development for the company's pipeline, especially for a small-cap entity, as it introduces a new drug candidate with favorable preclinical data and an accelerated timeline for an IND application by late 2026. The 50/50 cost-sharing arrangement for the LA-PTH program with a larger partner like OPKO Health substantially de-risks development for Entera Bio. Furthermore, the appointment of Steven D. Rubin, an Executive Vice President from OPKO Health, to Entera's Board of Directors and as Chairman of the audit committee, strengthens the strategic alignment and governance, bringing valuable financial expertise. This positive news comes as the company's stock is trading near its 52-week lows, potentially offering a boost to investor sentiment.
At the time of this filing, ENTX was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.4M. The 52-week trading range was $1.23 to $3.22. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.